Regulatory feed
Published med-spa & injectable compliance alerts · monitoring, not legal advice
Free weekly Brief
Get the changes that matter in plain English, every week — and be alerted when the rules move. No charge.
Members get a specific “what to do” wherever a change calls for one — in one daily email, for your states. See one unlocked → · Pricing →
Border enforcement · last 90 days
FDA Import Refusals · counts of published records
FDA refused 201 shipments of unapproved or violative injectables at the U.S. border from 111 firms across 22 countries — the gray-market corridor to source away from.
| Product class | Shipments | Firms | Countries |
|---|---|---|---|
| Dermal fillersincl. QUIVER MEDIC INC., Q-Med AB, Daehan Nupharm | 114 | 71 | 18 |
| Botulinum toxinincl. Medytox Inc., Allergan Pharmaceuticals Ireland, COMEM NATURAL JSC | 52 | 21 | 7 |
| GLP-1 drugsincl. ELI LILLY JAPAN, TANDJIGORA MOHAMED, Eli Lilly Italia SPA | 21 | 14 | 10 |
| Injectable anestheticsincl. BIOPHARMA, Daehan Nupharm, SANKALP HEALTHCARE | 14 | 14 | 8 |
Source: FDA Data Dashboard import refusals. A refusal is a border action, not a finding against any U.S. practice. Named firms are the foreign shippers/manufacturers on FDA’s record.
Showing material changes. 362 routine background items are collapsed.
Show everything →- CAUTIONWIScope of PracticeSep 21, 2026
WI State Administrative Register: 849A3 Register (9/21/2026) - 2026-09-21
Wisconsin Board of Nursing emergency rules affecting APRNs.
What to do — members only.Become a member →State Administrative Registerprimary source ↗ - MONITORFEDMulti-topicSep 21, 2026
Primary Source Monitoring: Former Connecticut Resident Guilty of Operating Websites to Illegally Sell Misbranded and Unapproved Drugs
Caution urged due to recent conviction for selling misbranded drugs.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORFEDDermal FillersSep 17, 2026
Primary Source Monitoring: Korea Filler Experts - 718706 - 11/03/2025
FDA warns koreafillerexperts.com over unapproved, misbranded injectable botulinum toxin.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORFEDGLP-1 CompoundingSep 16, 2026
Primary Source Monitoring: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
FDA updates compounding guidelines as GLP-1 supplies stabilize.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - CRITICALFEDAesthetic DevicesSep 16, 2026
FDA device recall (Class II): Product Name: DermaV Laser System Model/Catalog Number: DermaV Medical laser device that delivers pulsed laser energy a…
FDA recalls DermaV Laser System; check for safety compliance.
What to do — members only.Become a member →FDA Device Recallprimary source ↗ - MONITORFEDGLP-1 CompoundingSep 15, 2026
Primary Source Monitoring: Hefner v. Rock Valley Compounding Pharmacy, LLC (3:26-cv-01298) — District Court, S.D. Illinois
Legal case filed affecting compounding pharmacy standards.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - CAUTIONWIScope of PracticeSep 14, 2026
WI State Administrative Register: 849A2 Register (9/14/2026) - 2026-09-14
Emergency rule from Wisconsin Board of Nursing may impact injectors.
What to do — members only.Become a member →State Administrative Registerprimary source ↗ - MONITORFEDGLP-1 CompoundingSep 9, 2026
Primary Source Monitoring: Human Drug Compounding Policies and Rules
FDA's compounding policy index adds a September 2026 neonatal nutrition guidance.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORFEDGLP-1 CompoundingSep 4, 2026
Primary Source Monitoring: Eli Lilly v. Instant Rx (E.D.N.Y.) — Consent Judgment and Permanent Injunction as to defendants Dispensing Physician Consultants, Inc. d/b/a Ira's Di…
Injunction against suppliers may impact GLP-1 access for med spas.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORFEDMulti-topicSep 4, 2026
Primary Source Monitoring: Med Spa Owner Sentenced to 46 Months in Prison for Performing Thousands of Counterfeit Botox and Filler Injections
Med spa owner sentenced for using counterfeit Botox and fillers.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORWAScope of PracticeSep 3, 2026
WA State Health Agency: Registered Nurse (RN) and Licensed Practical Nurse (Lpn) Licensing Requirements
RN and LPN licensing rules in Washington may affect aesthetic practices.
What to do — members only.Become a member →State Health Agencyprimary source ↗ - MONITORFEDPeptidesSep 1, 2026
Primary Source Monitoring: Peak Performance Peptides - 735127 - 08/24/2026
FDA warns about unapproved peptide products; assess your suppliers.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - CAUTIONWIScope of PracticeAug 31, 2026
WI State Administrative Register: 848B Register (8/31/2026) - 2026-08-31
Wisconsin updates may alter scope-of-practice for injectors.
What to do — members only.Become a member →State Administrative Registerprimary source ↗ - MONITORFEDGLP-1 CompoundingAug 28, 2026
Primary Source Monitoring: Agency Information Collection Activities; Proposals, Submissions, and Approvals: Registration of Human Drug Compounding Outsourcing Facilities Under …
FDA proposals may impact compounding practices for med spas.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - CAUTIONWIScope of PracticeAug 28, 2026
WI State Administrative Register: Register 848 - Inserted Chapter Sps 382 - 2026-08-28
Supervision standards for aesthetic practices in Wisconsin.
What to do — members only.Become a member →State Administrative Registerprimary source ↗ - CAUTIONWIScope of PracticeAug 28, 2026
WI State Administrative Register: Register 848 - Removed Chapter Sps 382 - 2026-08-28
Key supervision standards for med spas may have changed.
What to do — members only.Become a member →State Administrative Registerprimary source ↗ - CAUTIONOHLasers/EnergyAug 26, 2026
OH HB377: Regards use of light-based medical devices for hair removal
Ohio HB 377 sets supervision rules for light-based hair removal.
What to do — members only.Become a member →LegiScanprimary source ↗ - MONITORFEDMulti-topicAug 25, 2026
Primary Source Monitoring: Drug Shortages | Additional News and Information
Stay informed about updated drug shortages affecting aesthetics.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - CAUTIONFEDAesthetic DevicesFDA: VAIAug 25, 2026
FDA Warning Letter: Advance-Esthetic LLC (Devices)
FDA says Zemits CrystalFrax Pro, Abigon Pro and Bionexis Lite Pro RF and light body-contouring devices lack required FDA approval or clearance.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - CAUTIONFEDGLP-1 CompoundingAug 24, 2026
FDA Warning Letter: Peptide Partners, LLC (Drugs)
FDA says Peptide Partners' "research use only" GLP-1s and other injectable peptides are unapproved drugs. Health claims on its own product pages were FDA's evidence that they were intended for human use.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - CAUTIONFEDGLP-1 CompoundingAug 24, 2026
FDA Warning Letter: Royal Peptides LLC (Drugs)
FDA says Royal Peptides' "research use only" GLP-1s and other peptides are unapproved drugs. Its weight-loss claims, and the bacteriostatic water, "peptide guide" and "peptide calculator" sold alongside them, were FDA's evidence they were meant for injection in people.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - CAUTIONFEDGLP-1 CompoundingAug 24, 2026
FDA Warning Letter: Peak Performance Peptides (Drugs)
FDA says Peak Performance Peptides' "research use only" semaglutide, retatrutide and other peptides, and the BAC water sold with them, are unapproved.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - MONITORFEDMulti-topicAug 21, 2026
Primary Source Monitoring: Compounding Information for States
FDA issues new compounding guidance; check for local implications.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORFEDMulti-topicAug 21, 2026
Primary Source Monitoring: Compounding and the FDA: Questions and Answers
FDA guidance on compounding released; impact on med spas unclear.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - CRITICALFEDGLP-1 CompoundingAug 19, 2026
FDA recall (Class II): Semaglutide 6.75mg (4.5 mg/mL), 1.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, Apollo care, …
Recall of semaglutide from Apollo Care due to contamination risk.
What to do — members only.Become a member →FDA Enforcementprimary source ↗ - MONITORFEDGLP-1 CompoundingAug 17, 2026
Primary Source Monitoring: Illinois Man Charged With Scheme To Impersonate Doctors And Make False Statements To Obtain GLP-1 Medications
Fraud case underlines risks in GLP-1 medication practices.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORFEDPeptidesAug 12, 2026
Primary Source Monitoring: Eli Lilly and Company v. Lone Star Peptide Co. LLC (4:26-cv-06562) — District Court, S.D. Texas
Eli Lilly's lawsuit may impact peptide supply chains for med spas.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORWIMulti-topicAug 10, 2026
WI State Administrative Register: Emergency Rules Filed with Legislative Reference Bureau - 2026-08-10
Emergency rules may impact licensure practices in Wisconsin.
What to do — members only.Become a member →State Administrative Registerprimary source ↗ - CAUTIONILMulti-topicAug 7, 2026
IL HB5000: Health Facilities Planning
Ownership rules for health care facilities in Illinois affect med spas.
What to do — members only.Become a member →LegiScanprimary source ↗ - MONITORWIMulti-topicAug 3, 2026
WI State Administrative Register: 848A1 Register (8/3/2026) - 2026-08-03
Wisconsin nursing rule update may impact med spa regulations.
What to do — members only.Become a member →State Administrative Registerprimary source ↗ - MONITORFEDMulti-topicJul 31, 2026
Primary Source Monitoring: Illinois Man and Indiana Woman Sentenced Respectively to 70 Months and 16 Months in Prison For Selling Unapproved Drugs in Interstate Commerce
Sentencing for selling unapproved drugs serves as a warning.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORFEDGLP-1 CompoundingJul 30, 2026
FDA / Federal Register Notice: Outsourcing Facility Fee Rates for Fiscal Year 2027
FDA fees for outsourcing facilities will impact med spas using compounds.
What to do — members only.Become a member →Federal Registerprimary source ↗ - MONITORFEDMulti-topicJul 17, 2026
Primary Source Monitoring: Wilson v. Lexington Compounding Pharmacy, Inc. (5:26-cv-00273) — District Court, E.D. Kentucky
No immediate changes for med spas from recent court case findings.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - CRITICALFEDMulti-topicFDA: OAIJul 8, 2026
FDA Warning Letter: Spa De Soleil, Inc. (Drugs)
Water Spa De Soleil uses to make over-the-counter topical products failed testing 51 times from 2024 to 2025. FDA had cited similar problems in 2021.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - MONITORFEDMulti-topicJul 1, 2026
Primary Source Monitoring: Massachusetts Couple Sentenced to Prison for Importing Misbranded Drugs From China and Selling Them to Customers in U.S. for Performance Enhancing Pu…
A couple was sentenced for selling misbranded drugs in the U.S.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORFEDMulti-topicJun 29, 2026
Primary Source Monitoring: Pagan v. Glow Med Spa (1:26-cv-24474) — District Court, S.D. Florida
Americans with Disabilities Act lawsuit filed against a Florida med spa.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORFEDGLP-1 CompoundingJun 26, 2026
FDA / Federal Register Notice: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period
FDA extends comment period on GLP-1 compounding decisions.
What to do — members only.Become a member →Federal Registerprimary source ↗ - CAUTIONALMulti-topicJun 25, 2026
AL Primary Source Monitoring: Proposed Rule Changes
Stay informed about proposed rule changes in Alabama.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - CAUTIONFEDMulti-topicJun 23, 2026
FDA Warning Letter: ketaminelab.org (Drugs)
FDA says buyketaminepowderonline.com (formerly ketaminelab.org) sells unapproved, misbranded ketamine powder online.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - CAUTIONFEDPeptidesJun 17, 2026
FDA Warning Letter: Wholesale Peptide (Drugs)
FDA says Wholesale Peptide's injectable "Prostamax" and gonadorelin are unapproved new drugs.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - CAUTIONFEDGLP-1 CompoundingJun 17, 2026
FDA Warning Letter: Herbal Dermals Ltd (Drugs)
Herbal Dermals Ltd received an FDA Warning Letter; verify details.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - CAUTIONFEDMulti-topicJun 17, 2026
FDA Warning Letter: Herbal Dermals LLC Fz (Drugs)
FDA says Gotucream, sold online as a balanitis treatment cream, is an unapproved new drug.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - CAUTIONFEDGLP-1 CompoundingJun 17, 2026
FDA Warning Letter: Herbal Dermals Ltd (Drugs)
FDA issued a Warning Letter to Herbal Dermals Ltd.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - CAUTIONFEDGLP-1 CompoundingJun 17, 2026
FDA Warning Letter: Herbal Dermals Ltd (Drugs)
FDA Warning Letter issued to Herbal Dermals Ltd.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - CAUTIONFEDMarketing & AdvertisingJun 12, 2026
FTC Files Contempt Motion Against Amare Global and Three Individuals Over Unsubstantiated Health Claims
FTC targets deceptive health claims affecting aesthetic practices.
What to do — members only.Become a member →FTC Enforcementprimary source ↗ - MONITORFEDGLP-1 CompoundingJun 11, 2026
FDA shortage: Liraglutide Injection (Injection) — Currently in Shortage
Liraglutide remains compounded under shortage status.
What to do — members only.Become a member →FDA Drug Shortagesprimary source ↗ - MONITOROHScope of PracticeJun 9, 2026
OH HB963: Revise the law governing the practice of physician assistants
Changes to PAs' practice could affect med spa operations.
What to do — members only.Become a member →LegiScanprimary source ↗ - MONITORGAMulti-topicJun 5, 2026
GA State Medical Board: Gcmb Statement Regarding: IV Hydration/Therapy Position Statement | June 5, 2026
Georgia issues a position statement on IV hydration therapy.
What to do — members only.Become a member →State Medical Boardprimary source ↗ - CRITICALFEDGLP-1 CompoundingMay 27, 2026
FDA recall (Class II): Liraglutide Injection, 18 mg/3 mL (6 mg/mL), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, Fl 34108, …
FDA recalls contaminated Liraglutide Injection.
What to do — members only.Become a member →FDA Enforcementprimary source ↗ - MONITORCAGLP-1 CompoundingMay 27, 2026
CA SB1089: Preventive Treatment Health Care Act.
California bill to have the state negotiate GLP-1 anti-obesity drug pricing; sent to the Governor.
What to do — members only.Become a member →LegiScanprimary source ↗ - CAUTIONFEDGLP-1 CompoundingMay 26, 2026
Primary Source Monitoring: Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Fo…
FDA requests comments on drug compounding information collection.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORGAMulti-topicMay 19, 2026
GA State Medical Board: IV Hydration/Therapy Position Statement
Georgia board issues guidance on IV hydration therapies.
What to do — members only.Become a member →State Medical Boardprimary source ↗ - MONITORFEDNeuromodulatorsMay 19, 2026
Primary Source Monitoring: California Doctor Convicted of $45M Botox Fraud Scheme Targeting Medicare
California doctor convicted in Botox fraud scheme.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - CRITICALFEDGLP-1 CompoundingFDA: OAIMay 12, 2026
FDA Warning Letter: Fresenius Kabi Compounding, LLC (Drugs)
FDA Warning Letter issued to Fresenius Kabi Compounding, LLC.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - MONITORFEDMulti-topicMay 8, 2026
Primary Source Monitoring: Med Spa Owner Pleads Guilty to Performing Illegal Injections Using Unapproved Prescription Drugs
Guilty plea highlights risks of using unapproved injections.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORFEDGLP-1 CompoundingMay 1, 2026
FDA / Federal Register Notice: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act
FDA evaluates bulk drug substances; GLP-1 agents may be impacted.
What to do — members only.Become a member →Federal Registerprimary source ↗ - MONITORFEDMulti-topicApr 30, 2026
Primary Source Monitoring: Advisory Committee; Pharmacy Compounding Advisory Committee; Renewal
Pharmacy Compounding Advisory Committee renewed for continued oversight.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORCOMulti-topicApr 23, 2026
CO SB130: Medical Spas Deceptive Trade Practices
Colorado med spa drug-practices bill; postponed indefinitely in committee.
What to do — members only.Become a member →LegiScanprimary source ↗ - CRITICALTNNATIONALScope of PracticeApr 23, 2026
TN HB2044: an Act to amend Tennessee Code Annotated, Title 63; Title 68, Chapter 11, Part 2 and Chapter 1042 of the Public Acts of 2024, relative to certified medical assistants.
Tennessee HB 2044 on delegating aesthetic injections to certified MAs.
What to do — members only.Become a member →LegiScanprimary source ↗ - CRITICALFEDMulti-topicFDA: OAIApr 22, 2026
FDA Warning Letter: Active Cosmetics Manufacturing Inc (Drugs)
FDA cites Active Cosmetics Manufacturing for releasing OTC topical drugs after failed microbial tests, including S. aureus.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - MONITORFEDGLP-1 CompoundingApr 22, 2026
FDA recall (Class II): Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Bea…
FDA recalls semaglutide compound over sterility issues.
What to do — members only.Become a member →FDA Enforcementprimary source ↗ - CAUTIONFEDMulti-topicFDA: OAIApr 20, 2026
FDA Warning Letter: Foshan Miwei Cosmetics Co., Ltd. (Drugs)
FDA cites Foshan Miwei Cosmetics for releasing OTC drug products without testing active-ingredient strength or microbes.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - MONITORFEDGLP-1 CompoundingApr 16, 2026
Primary Source Monitoring: Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for…
Pharmacy Compounding Advisory Committee discusses new bulk substances.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORCTScope of PracticeApr 9, 2026
CT HB05399: An Act Concerning Dentistry.
CT bill updates dental assistant regulations for aesthetic procedures.
What to do — members only.Become a member →LegiScanprimary source ↗ - CAUTIONMEMulti-topicApr 8, 2026
ME LD2201: An Act to Implement Certain Recommendations Related to the Regulatory Review and Approval of Certain Health Care Transactions Involving Private Equity Companies, Hedge Funds or Management Services Organizations from the Commission to Evaluate the Scope of Regulatory Review and Oversight over Health Care Transactions That Impact the Delivery of Health Care Services in the State
Notification rules impact med spas working with private equity.
What to do — members only.Become a member →LegiScanprimary source ↗ - MONITORFEDMulti-topicApr 7, 2026
Primary Source Monitoring: Med Spa Owner Pleads Guilty to Performing Thousands of Injections Using Counterfeit Products
Med spa owner guilty of using counterfeit injection products.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - CAUTIONFEDMulti-topicApr 2, 2026
FDA Warning Letter: Purolea Cosmetics Lab (Drugs)
FDA cites Purolea Cosmetics Lab for insects and filth in its plant and for untested homeopathic drug products.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - MONITORFEDScope of PracticeApr 1, 2026
Primary Source Monitoring: Utah Licensed Osteopathic Physician Indicted for Allegedly Receiving Misbranded Drugs from China and Selling them to Patients
Indictment of a physician raises concerns for med spas on drug sourcing.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - CAUTIONFEDMulti-topicApr 1, 2026
FDA Warning Letter: Pure Indulgence Aesthetics (Drugs)
FDA says a Texas med spa administered far more Botox than it bought from AbbVie, and so had sourced toxin from unauthorized suppliers.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - CAUTIONFEDGLP-1 CompoundingMar 31, 2026
FDA Warning Letter: Mile High Compounds (Drugs)
FDA says the "research-only" semaglutide, tirzepatide and retatrutide sold by Mile High Compounds are unapproved injectable drugs. The firm's own weight-loss dosing guides, shared through its online forum, were FDA's evidence that the products were meant for people.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - CAUTIONFEDGLP-1 CompoundingMar 31, 2026
FDA Warning Letter: Gram Peptides (Drugs)
FDA says GRAM Peptides' "research use only" retatrutide and tirzepatide, sold with bacteriostatic water, are unapproved drugs.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - MONITORKYScope of PracticeMar 27, 2026
KY HB885: an Act relating to cosmetology.
Supervision requirements for esthetic practices in Kentucky.
What to do — members only.Become a member →LegiScanprimary source ↗ - CAUTIONFEDAesthetic DevicesMar 18, 2026
FDA device recall (Class II): Clarity II Laser System; Model No. 1110200210.
FDA recalls Clarity II Laser System for safety concerns.
What to do — members only.Become a member →FDA Device Recallprimary source ↗ - CAUTIONFLScope of PracticeMar 13, 2026
FL H1429: Licensure of Medical Spas
Florida med spa licensure bill; died in subcommittee.
What to do — members only.Become a member →LegiScanprimary source ↗ - CAUTIONFEDGLP-1 CompoundingMar 11, 2026
FDA recall (Class II): Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 843…
FDA recalls specific compounded GLP-1 products due to quality issues.
What to do — members only.Become a member →FDA Enforcementprimary source ↗ - CRITICALFEDGLP-1 CompoundingMar 11, 2026
FDA recall (Class II): Semaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, Ks 66061,…
FDA recalls Semaglutide for sterility issues.
What to do — members only.Become a member →FDA Enforcementprimary source ↗ - CAUTIONFEDGLP-1 CompoundingMar 11, 2026
FDA recall (Class II): Tirzepatide Inj, 15mg x 4, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, Ks 66061, …
FDA recalls Tirzepatide Inj over sterility concerns.
What to do — members only.Become a member →FDA Enforcementprimary source ↗ - CAUTIONINNATIONALMulti-topicMar 5, 2026
IN SB0282: Compounding drugs; registration of medical spas.
Indiana med spas must register with the licensing board by Jan 1, 2027.
What to do — members only.Become a member →LegiScanprimary source ↗ - MONITORWVScope of PracticeMar 2, 2026
WV SB486: Relating to Wv Board of Barbers and Cosmetologists
'Master aesthetician' role expands service capabilities in WV.
What to do — members only.Become a member →LegiScanprimary source ↗ - MONITORFEDGLP-1 CompoundingFeb 23, 2026
Primary Source Monitoring: Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Human Drug Compounding Under Sectio…
Comment period open on federal compounding information requirements.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORWVScope of PracticeFeb 16, 2026
WV HB5538: To expand licensing opportunities and safety regulation in the esthetics industry
Licensing bill expands esthetics practices in WV.
What to do — members only.Become a member →LegiScanprimary source ↗ - MONITORRIOwnership/CPOMFeb 12, 2026
RI H7721: Establishes the Rhode Island Ban on the Corporate Practice of Medicine Act.
RI Bill H7721 may change corporate practice for med spas.
What to do — members only.Become a member →LegiScanprimary source ↗ - MONITORAZScope of PracticeFeb 10, 2026
AZ HB4047: Medical spas; licensure; regulation
Licensure requirements for med spas in Arizona.
What to do — members only.Become a member →LegiScanprimary source ↗ - MONITORHIGLP-1 CompoundingJan 28, 2026
HI SB3195: Relating To Drugs For Weight Loss.
HI SB3195 mandates coverage for GLP-1 weight loss drugs.
What to do — members only.Become a member →LegiScanprimary source ↗ - MONITORFEDAesthetic DevicesJan 28, 2026
FDA device recall (Class II): Brand Name: Leaseir Product Name: Leaseir Mhr Xcell Model/Catalog Number: Mhr 110-b Software Version: 1.5.0.0 Product D…
Leaseir MHR Xcell laser recalled for safety issues.
What to do — members only.Become a member →FDA Device Recallprimary source ↗ - MONITORMAMulti-topicJan 27, 2026
MA H5087: Regulating the operation of medical spas
Proposed Massachusetts med spa bill; superseded by a new draft, H5455.
What to do — members only.Become a member →LegiScanprimary source ↗ - MONITORIAScope of PracticeJan 20, 2026
IA HSB591: A bill for an act establishing the medical spa oversight Act, and making penalties applicable.
Proposed Iowa Medical Spa Oversight Act, with penalties.
What to do — members only.Become a member →LegiScanprimary source ↗ - CRITICALFEDGLP-1 CompoundingJan 7, 2026
FDA recall (Class II): Wegovy (Semaglutide) Injection, 0.5 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880…
FDA recalls Wegovy; med spas must check supplies.
What to do — members only.Become a member →FDA Enforcementprimary source ↗ - MONITORFEDMulti-topicDec 18, 2025
Primary Source Monitoring: Doctor Indicted for Orchestrating $45M Botox Fraud Scheme Targeting Medicare
Doctor indicted in $45M Botox fraud scheme targeting Medicare.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORPAScope of PracticeDec 16, 2025
PA HB1881: Further providing for pharmacy technician and pharmacy technician trainee registration, qualifications and supervision; providing for administration of injectable medications, biologicals and immunizations, for clinical laboratory certificate and for report on pharmacy-administered vaccines; and making a repeal.
PA bill may expand pharmacy technicians' role in injectables.
What to do — members only.Become a member →LegiScanprimary source ↗ - MONITORFEDScope of PracticeDec 12, 2025
Primary Source Monitoring: Med Spa Owner Agrees to Plead Guilty to Performing Illegal Injections Using Unapproved Prescription Drugs
Legal repercussions for med spas using unapproved injection drugs.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORFEDScope of PracticeDec 3, 2025
Primary Source Monitoring: Southern New Mexico Medical Spa Operator Settles Allegations of Controlled-Substance Recordkeeping Violations
Med spa operator faces penalties for recordkeeping violations.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - CAUTIONFEDGLP-1 CompoundingNov 5, 2025
FDA recall (Class II): Semaglutide Injection, 2.5mg/1mL (2.5 mg/mL), 1mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jef…
Urgent: FDA recalls compounded semaglutide injection.
What to do — members only.Become a member →FDA Enforcementprimary source ↗ - MONITORFEDGLP-1 CompoundingNov 5, 2025
FDA recall (Class II): Tirzepatide Injection, 27 mg/3 mL (9 mg/mL), 3mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeff…
Urgent FDA recall of Tirzepatide Injection impacts med spas.
What to do — members only.Become a member →FDA Enforcementprimary source ↗ - MONITORFEDGLP-1 CompoundingOct 15, 2025
FDA recall (Class II): Semaglutide with B12 for Injection, all strengths and presentations, GenoGenix, LLC, 2840 Nw 2nd Ave Ste 204 Boca Raton…
FDA recalls GLP-1 product over sterility issues.
What to do — members only.Become a member →FDA Enforcementprimary source ↗ - MONITORFEDGLP-1 CompoundingOct 15, 2025
FDA recall (Class II): Tirzepatide, 60mg/10 mL for Injection, 10mL vial lyophilized, all presentations, GenoGenix, LLC, 2840 Nw 2nd Ave Ste 20…
Important FDA recall on GLP-1 compounded product.
What to do — members only.Become a member →FDA Enforcementprimary source ↗ - CRITICALFEDGLP-1 CompoundingSep 10, 2025
FDA recall (Class II): Semaglutide, 2.5 mg/mL injection, 2 mL., Boothwyn Pharmacy
FDA recalls compounded GLP-1 product for being subpotent.
What to do — members only.Become a member →FDA Enforcementprimary source ↗ - CRITICALFEDGLP-1 CompoundingAug 13, 2025
FDA recall (Class II): Semaglutide + Cyanocobalamin 2.67 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Steri…
FDA recalls compounded GLP-1 product.
What to do — members only.Become a member →FDA Enforcementprimary source ↗ - CRITICALFEDGLP-1 CompoundingAug 13, 2025
FDA recall (Class II): Tirzepatide + Niacinamide 16.6 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, …
Important recall for GLP-1 products; take immediate action.
What to do — members only.Become a member →FDA Enforcementprimary source ↗ - MONITORFEDGLP-1 CompoundingJul 30, 2025
FDA / Federal Register Notice: Outsourcing Facility Fee Rates for Fiscal Year 2026
FDA fees for outsourcing facilities impact compounding.
What to do — members only.Become a member →Federal Registerprimary source ↗ - CRITICALFEDGLP-1 CompoundingJul 2, 2025
FDA recall (Class II): Tirzepatide Injections, 30mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewo…
FDA recalls Tirzepatide injections; action needed.
What to do — members only.Become a member →FDA Enforcementprimary source ↗ - CRITICALFEDGLP-1 CompoundingJul 2, 2025
FDA recall (Class II): Semaglutide, 2.5 mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, Co 80…
FDA recalls GLP-1 product over sterility issues.
What to do — members only.Become a member →FDA Enforcementprimary source ↗ - CAUTIONRINATIONALScope of PracticeJun 30, 2025
RI H5351: Mandates cosmetic medical procedures be performed by a physician, PA, APRN, or delegated to a qualified non-physician, non-PA or non-APRN under the supervision of a physician, physician assistant, or advanced practice registered nurse.
Major changes in who can perform cosmetic procedures in RI med spas.
What to do — members only.Become a member →LegiScanprimary source ↗ - CAUTIONTXNATIONALScope of PracticeJun 20, 2025
TX HB3749: Relating to the regulation of the provision of elective intravenous therapy.
Texas HB 3749 regulates elective IV therapy; effective Sept 1, 2025.
What to do — members only.Become a member →LegiScanprimary source ↗ - MONITORTXScope of PracticeMay 15, 2025
TX SB2696: Relating to the regulation of the performance of cosmetic injections; requiring an occupational certificate; authorizing fees.
Certification required for cosmetic injectors in Texas by 2026.
What to do — members only.Become a member →LegiScanprimary source ↗ - MONITORTXNeuromodulatorsMay 8, 2025
TX SB1117: Relating to the administration of botulinum toxin by dentists.
TX SB1117 allows dentists to inject botulinum toxin by 2025.
What to do — members only.Become a member →LegiScanprimary source ↗ - CRITICALFEDGLP-1 CompoundingMay 7, 2025
FDA recall (Class II): Wegovy (Semaglutide) injection, 2.4 mg/0.75 mL, 4 Single-Dose Prefilled Pens per Carton, For Subcutaneous Use Only, Rx …
Urgent recall of Wegovy due to temperature abuse risks.
What to do — members only.Become a member →FDA Enforcementprimary source ↗ - CAUTIONCOScope of PracticeApr 7, 2025
CO HB1024: Medical-Aesthetic Services Delegation Disclosures
Disclosure requirements for delegating medical-aesthetic services.
What to do — members only.Become a member →LegiScanprimary source ↗
Browse the full archive → Every material change on record, grouped by year — including changes older than the 18 months shown above.